Q/C TECHNOLOGIES, INC. — Regulatory Filings 2020

Apr 17, 2020

8-K 1 form8-k.htm

Field: Rule-Page

Field: /Rule-Page

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): April 17, 2020

AKERS BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

| New

Jersey	001-36268	22-2983783
(State
or other jurisdiction of	(Commission	(I.R.S.
Employer
incorporation
or organization)	File
Number)	Identification
Number)

201 Grove Road

Thorofare, New Jersey USA 08086

(Address of principal executive offices, including zip code)

(856) 848-8698

(Registrant’s telephone number, including area code)

Not Applicable (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

| [ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | | --- | --- | | [ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | | [ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | | [ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company [ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Securities registered pursuant to Section 12(b) of the Act:

| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | --- | --- | --- | | Common Stock, no par value | AKER | The NASDAQ Capital Market |

Field: Rule-Page

Field: /Rule-Page

Field: Page; Sequence: 1

Field: /Page

Item 8.01 Other Events.

From April 7, 2020, through April 16, 2020, warrants to purchase an aggregate of 1,043,500 shares of Series C Preferred Stock of Akers Biosciences, Inc. (the “Company”) were exercised at an exercise price of $4.00 per share of Series C Preferred Stock, which were immediately converted into an aggregate of 1,043,500 shares of the Company’s common stock. Following the warrant exercises and the conversion of shares of Series C Preferred Stock issued upon exercise of the warrants into shares of common stock, as of April 17, 2020, we have 4,755,407 shares of common stock issued and outstanding, and outstanding warrants to purchase 946,500 shares of Series C Preferred Stock, which would be convertible into an aggregate of 946,500 shares of common stock at the conversion price in effect as of April 17, 2020.

Field: Page; Sequence: 2

Field: /Page

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

| | AKERS BIOSCIENCES, INC. | | --- | --- | | Dated: April 17, 2020 | /s/ Christopher C. Schreiber | | | Christopher C. Schreiber | | | Executive Chairman of the Board of Directors and Director |

Field: Page; Sequence: 3

Field: /Page